VERV240517C20000
- 0.16
- 0.000.00%
Verve Therapeutics Newsroom
Verve Therapeutics Slides As Insider Purchases Lose Another US$55k
The recent price decline of 11% in Verve Therapeutics, Inc.'s (NASDAQ:VERV) stock may have disappointed insiders who bought US$475.8k worth of shares at an average price of US$6.26 in the past 12 mont
Verve Therapeutics Gains as COO Buys Shares
Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket
06:50 AM EDT, 05/16/2024 (MT Newswires) -- Verve Therapeutics CFO Andrew Ashe Executes Purchase of 76,000 Shares of Common Stock; Shares Jump Premarket Price: 6.65, Change: +0.42, Percent Change: +6.7
Verve Therapeutics(VERV.US) Officer Buys US$475.76K in Common Stock
$Verve Therapeutics(VERV.US)$ Officer Ashe Andrew D. purchased 76,000 shares of common stock on May 14, 2024 at an average price of $6.26 for a total value of $475.76K.Source: Announcement What is sta
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financials
Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week
Express News | HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
Verve Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 140.19% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/03/2024 540.51% Stifel $56 → $40 Main
RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential
Verve Therapeutics' Financial Outlook Threatened by CRISPR Patent Disputes
Express News | Verve Therapeutics Inc : Jefferies Cuts Target Price to $28 From $31
Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline
Verve Therapeutics | 10-Q: Quarterly report
Verve Therapeutics 1Q Rev $5.7M >VERV
Verve Therapeutics 1Q Rev $5.7M >VERV
Verve Therapeutics 1Q Loss/Shr 59c >VERV
Verve Therapeutics 1Q Loss/Shr 59c >VERV
Express News | Verve Therapeutics Inc - First Patient Dosed in Heart-2 Phase 1B Clinical Trial of Verve-102
Express News | Verve Therapeutics Inc - Verve-201 Clinical Trial Initiation on Track for Second Half of 2024
Express News | Verve Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities of $606.4 Mln; Cash Runway Into Late 2026
Express News | Verve Therapeutics Inc - Received First Milestone Payment From Eli Lilly for Collaboration on in Vivo Gene Editing Program Targeting Lipoprotein(a)